Head-to-head evidence
CID-103 vs Mezagitamab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
CID-103
Developed by CASI Pharmaceuticals, Inc.
NCT04758767 · Phase 1 · completed
All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Mezagitamab
Developed by Takeda Pharmaceutical Company
NCT03439280 · Phase 1/2 · completed
This was a nonrandomized, open-label, single-arm dose-escalation study of 50 participants, with no placebo or active comparator. Its primary outcomes focused on safety, including treatment-emergent adverse events and dose-limiting toxicities, rather than a controlled efficacy comparison; 50 of 50 participants reported at least one treatment-emergent adverse event, and 1 of 41 dose-limiting-toxicity-evaluable participants had a dose-limiting toxicity.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CID-103's landscape · Mezagitamab's landscape